Mulai

EPIX Big Push Forward - 86% Up IN ONE MONTH

172
ESSA Pharma, Inc. engages in the development of small molecule drugs for prostate cancer. It focuses on producing drugs which selectively block the amino-terminal domain (NTD) of the androgen receptor (AR), potentially overcoming the known AR-dependent resistance mechanisms of castration-resistant prostate cancer (CRPC), and providing CRPC patients with the potential for increased progression-free and overall survival. The company was founded by Marianne D. Sadar and Raymond J. Andersen on January 6, 2009 and is headquartered in Vancouver, Canada.

SHORT INTEREST
102.77K 08/15/19

P/E Current
-1.08

P/E Ratio (with extraordinary items)
-1.45

Average Recommendation: BUY

Average Target Price: 18.63
DEXWireNews
Juga di:
Beyond Technical AnalysisBullish PatternsEPIXHarmonic PatternsmonthpennystocksignalsStockstradingTrend Analysis

Pernyataan Penyangkalan

Informasi dan publikasi ini tidak dimaksudkan, dan bukan merupakan, saran atau rekomendasi keuangan, investasi, trading, atau jenis lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Ketentuan Penggunaan.
Beyond Technical AnalysisBullish PatternsEPIXHarmonic PatternsmonthpennystocksignalsStockstradingTrend Analysis
DEXWireNews
Juga di:

Pernyataan Penyangkalan

Informasi dan publikasi ini tidak dimaksudkan, dan bukan merupakan, saran atau rekomendasi keuangan, investasi, trading, atau jenis lainnya yang diberikan atau didukung oleh TradingView. Baca selengkapnya di Ketentuan Penggunaan.